LivaNova (NASDAQ:LIVN) Announces Earnings Results

LivaNova (NASDAQ:LIVN) released its quarterly earnings results on Wednesday. The company reported $0.73 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.45 by $0.28, Briefing.com reports. LivaNova had a return on equity of 12.23% and a net margin of 1.53%. The business had revenue of $294.90 million during the quarter, compared to the consensus estimate of $278.17 million. During the same period in the previous year, the company posted $0.43 EPS. The business’s quarterly revenue was up 12.0% compared to the same quarter last year. LivaNova updated its FY 2024 guidance to 3.050-3.150 EPS and its FY24 guidance to $3.05-3.15 EPS.

LivaNova Trading Up 0.5 %

Shares of LIVN traded up $0.30 during trading hours on Thursday, reaching $62.92. 1,378,704 shares of the company traded hands, compared to its average volume of 644,104. The firm has a market cap of $3.41 billion, a price-to-earnings ratio of 195.69 and a beta of 0.92. LivaNova has a 12-month low of $42.75 and a 12-month high of $63.21. The stock’s fifty day moving average price is $54.44 and its 200 day moving average price is $50.85. The company has a current ratio of 2.95, a quick ratio of 2.51 and a debt-to-equity ratio of 0.44.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Mizuho lifted their target price on LivaNova from $75.00 to $80.00 and gave the company a “buy” rating in a research report on Thursday. Needham & Company LLC reaffirmed a “buy” rating and set a $72.00 price objective on shares of LivaNova in a research report on Wednesday. StockNews.com upgraded shares of LivaNova from a “hold” rating to a “buy” rating in a research note on Thursday, April 25th. Robert W. Baird lifted their price target on shares of LivaNova from $58.00 to $66.00 and gave the company a “neutral” rating in a report on Thursday. Finally, Barclays increased their price objective on shares of LivaNova from $57.00 to $61.00 and gave the stock an “equal weight” rating in a research note on Monday, February 26th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $66.20.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.